Do you want to read an article? Please log in or register.
Efficacy and Speed of Induction of Remission of Infliximab vs Golimumab for Patients With Ulcerative Colitis, Based on Data From Clinical Trials
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderate-Severe Ulcerative Colitis and Crohn's Disease
Inflamm Bowel Dis.
George J, Singh S, Dulai PS, Ma C, Nguyen T, Feagan BG, Sandborn WJ, Jairath V
doi: 10.1093/ibd/izz193.
Inflammatory Bowel Disease
Safety and Efficacy of Tumor Necrosis Factor Antagonists in Older Patients With Ulcerative Colitis: Patient-Level Pooled Analysis of Data From Randomized Trials
Clin Gastroenterol Hepatol.
Cheng D, Cushing KC, Cai T, Ananthakrishnan AN
doi: 10.1016/j.cgh.2020.04.070.
Inflammatory Bowel Disease
Immunogenicity of Golimumab and its Clinical Relevance in Patients With Ulcerative Colitis
Inflamm Bowel Dis.
Adedokun OJ, Gunn GR 3rd, Leu JH, Gargano C, Xu Z, Sandborn WJ, Rutgeerts P5, Shankar G
doi: 10.1093/ibd/izz003.
Inflammatory Bowel Disease
Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis
Inflamm Bowel Dis.
Feagan BG, Schreiber S, Wolf DC, Axler JL, Kaviya A, James A, Curtis RI, Geransar P, Stallmach A, Ehehalt R, Bokemeyer B, Khalid JM, O'Byrne S
doi: 10.1093/ibd/izy323.
Inflammatory Bowel Disease
Intensified infliximab induction is associated with improved response and decreased colectomy in steroid-refractory paediatric ulcerative colitis
J Crohns Colitis.
Church PC, Ho S, Sharma A, Tomalty D, Frost K, Muise A, Walters TD,
Griffiths AM
doi: 10.1093/ecco-jcc/jjz019.
Further Publications
Comparative Efficacy for Infliximab vs. Vedolizumab in Biologic Naive Ulcerative Colitis
Clin Gastroenterol Hepatol
Narula N, Wong ECL, Marshall JK, Colombel JF, Dulai PS, Reinisch W
doi: 10.1016/j.cgh.2021.07.038
Inflammatory Bowel Disease
Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-based vs Trough Concentration-based Dosing of Infliximab
Clin Gastroenterol Hepatol.
Pouillon L, Ferrante M, Van Assche G, Rutgeerts P, Noman M, Sabino J, Vande Casteele N, Gils A, Vermeire S
doi: 10.1016/
Further Publications
Efficacy and Safety of Continued Treatment with Mirikizumab in a Phase 2 Trial of Patients with Ulcerative Colitis
★ 3
Recommended and commented by
PD Dr Luc Biedermann, Faculty Member
Clin Gastroenterol Hepatol
Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Hibi T, D'Haens GR, Tuttle JL, Krueger K, Friedrich S, Durante M, Arora V, Naegeli AN, Schmitz J, Feagan BG
doi: 10.1016/j.cgh.2020.09.028
Inflammatory Bowel Disease
Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis: Ustekinumab PK and exposure-response in UC
Clin Gastroenterol Hepatol.
Adedokun OJ, Xu Z, Marano C, O'Brien C, Szapary P, Zhang H, Johanns J, Leong RW, Hisamatsu T, van Assche G, Danese S, Abreu MT, Sands BE, Sandborn WJ
doi: 10.1016/j.cgh.2019.11.059.